Infliximab 5 mg/kg vs CT‐P13 biosimilar 5 mg/kg
Clinical response defined by reduction of CDAI score by ≥ 100 at week 6 · Patients with active Crohn's disease
Infliximab 5 mg/kg showed no clear difference in clinical response defined by reduction of CDAI score by ≥ 100 at… compared with CT‐P13 biosimilar 5 mg/kg (low certainty).
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 0.97 [0.79, 1.2]1 study · 220 participantsLow